Skip to main content
Premium Trial:

Request an Annual Quote

Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership

NEW YORK – Bioinformatics firm Qlucore said Monday that it is expanding into the area of bladder cancer diagnostics by entering into a partnership with Lund University.

The firm will work with the university in its hometown of Lund, Sweden, to develop and clinically validate classifier models for bladder cancer that will work in concert with machine learning-based algorithms for its Qlucore Diagnostics and Qlucore Insights software platforms. The company hopes that the work will help it achieve its previously stated goal of obtaining CE marking for Qlucore Diagnostics.

"This cooperation with another leading group will add a new disease area to the Qlucore suite of solutions and increase the uptake of molecular diagnostics for cancer," Qlucore CEO Carl-Johan Ivarsson said in a statement.

Qlucore will be working with Lund University senior scientists Fredrik Liedberg and Mattias Höglund, who developed the "Lund Taxonomy" for bladder cancer classification based on RNA expression analysis.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.